
    
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      different formulations of orally administered solabegron in healthy male subjects. Eligible
      male subjects will be enrolled into 2 cohorts of 12 subjects each conducted in parallel. The
      study is a single blind (subjects), randomized, cross-over design in 3 study periods.
    
  